Until now, it has been difficult to maintain retinal ganglion cells deep inside organoids over extended periods. The supply of nutrients and oxygen in the densely packed tissues is limited, leading to ...

Newcells provides a quick and accurate in vitro retinal drug toxicity testing service using intricate retinal organoid models created in-house or from client-supplied cells. The retinal toxicity ...

Axol Bioscience, a leading provider of human induced pluripotent stem cell (iPSC) technologies, has acquired the ophthalmology business of Newcells Biotech, a specialist in in vitro retinal ...

The research team of Robyn Jamieson from Children’s Medical Research Institute, University of Sydney, Australia have now set up a lab-based testing platform to classify variants of uncertain ...

Retinal degeneration is a leading cause of blindness globally and results from irreversible damage to photoreceptors and supporting cells including retinal pigment epithelium (RPE). Scientists have ...

Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, a specialist in the development of in vitro models and bespoke assay services based in Newcastle upon Tyne.

A retinal organoid examined at an early stage of differentiation shows different cells visualized by immunocytochemistry. Photo courtesy of Kim Edwards. MADISON — Inside the human eye, the retina is ...

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, today announced that it has acquired the ophthalmology business of ...

Humans develop sharp vision during early fetal development thanks to an interplay between a vitamin A derivative and thyroid hormones in the retina, Johns Hopkins University scientists have found. The ...